Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Having lived with disabling chronic pain for 32 years, one woman discovered a lesser known treatment that has transformed her life “I was told that my pain would last for the rest of my life ...

Table 1. Comparison of 12-month major molecular response rates with front-line imatinib, dasatinib and nilotinib therapy. Trials Study groups 12-month major molecular response (%) Ref.

Although the effectiveness of imatinib in CML was due to potent inhibition of the BCR-ABL fusion protein, its successful commercial development facilitated investigation of the drug's other kinase ...

Swap your mattress and buy well-fitting footwear – these are just two of the small changes experts believe will keep long-term pain at bay Any kind of pain that lasts longer than three months is ...